Global Veterinary Anti-infectives Market Size study, by Animal Type, Product (Antibacterials, Antifungals), Route Of Administration, Type, Distribution Channel and Regional Forecasts 2022-2032

Global Veterinary Anti-infectives Market is valued approximately at USD 7.88 billion in 2023 and is anticipated to grow with a steady growth rate of more than 5.30% over the forecast period 2024–2032. In the evolving world of veterinary healthcare, anti-infectives have emerged as a frontline defense against the rising tide of bacterial and fungal infections afflicting both companion and livestock animals. These agents—primarily antibacterials and antifungals—serve a critical role in preserving animal welfare, preventing zoonotic disease transmission, and sustaining productivity in animal agriculture. With the intensification of global meat and dairy demand, the veterinary anti-infectives sector is becoming increasingly essential in enabling preventive health protocols, ensuring biosecurity, and supporting antibiotic stewardship programs across veterinary settings.

The market’s momentum is being propelled by heightened awareness of infectious diseases, accelerated R&D in veterinary pharmacology, and the regulatory push for prudent antimicrobial use. Livestock farmers and pet owners alike are adopting these therapies to manage infections swiftly and cost-effectively, thereby reducing economic losses and animal suffering. Moreover, the development of advanced drug formulations—such as long-acting injectables, sustained-release oral products, and species-specific compounds—is enhancing treatment adherence and clinical outcomes. Technological advancements in diagnostic tools further complement this trend, allowing for early and accurate detection, thereby optimizing the deployment of anti-infectives and reducing the risk of antimicrobial resistance (AMR).

Nevertheless, the market faces several headwinds. Regulatory constraints surrounding antimicrobial usage, especially in food-producing animals, are tightening across North America and Europe. Additionally, the high cost of development and rigorous approval pathways for new veterinary pharmaceuticals often discourage innovation, particularly in antifungal segments. In rural and underserved markets, limited access to veterinary care and diagnostic infrastructure further restricts the responsible and effective use of these medications. However, these barriers are gradually being addressed through strategic public–private partnerships, educational initiatives for responsible usage, and digital health platforms that offer telemedicine support to farmers and animal health workers.

The integration of AI and precision medicine in veterinary health is unlocking transformative possibilities. Personalized dosing, predictive infection modeling, and data-driven supply chain optimization are reshaping how anti-infectives are administered and monitored. Meanwhile, veterinary pharmaceutical giants are shifting focus toward injectable biologics and combination therapies that reduce resistance development while offering broad-spectrum coverage. Emerging biotech startups are also stepping into the fray, targeting niche fungal infections and neglected zoonotic pathogens with novel formulations. Together, these dynamics are aligning the industry toward a future where targeted, efficient, and responsible use of anti-infectives becomes the gold standard.

Regionally, North America dominates the veterinary anti-infectives landscape, backed by a sophisticated veterinary infrastructure, extensive pet insurance coverage, and robust investments in animal drug R&D. Europe follows with strong regulatory frameworks encouraging antimicrobial stewardship and animal welfare compliance. Asia Pacific is poised to grow at the fastest pace, fueled by the rapid commercialization of livestock sectors in India and China, expanding veterinary care access, and government-led disease eradication campaigns. Latin America and the Middle East & Africa are gradually emerging, driven by improving veterinary education and the modernization of agriculture-dependent economies.

Major market player included in this report are:
• Zoetis Inc.
• Elanco Animal Health
• Ceva Santé Animale
• Merck Animal Health
• Vetoquinol S.A.
• Dechra Pharmaceuticals PLC
• Boehringer Ingelheim
• Bayer Animal Health
• Virbac
• Norbrook Laboratories
• Neogen Corporation
• Kyoritsu Seiyaku Corporation
• Chanelle Pharma
• Orion Corporation
• Jurox Pty Ltd

The detailed segments and sub-segment of the market are explained below:

By Animal Type
• Companion Animals

o Dogs

o Cats

o Others
• Livestock Animals

o Cattle

o Poultry

o Swine

o Others

By Product
• Antibacterials
• Antifungals

By Route Of Administration
• Oral
• Parenteral
• Topical
• Others

By Type
• Prescription
• Over the Counter (OTC)

By Distribution Channel
• Veterinary Hospitals
• Retail Pharmacies
• Online Pharmacies
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.